Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea

Jeong Yup Kim, Young Youl Hyun, Ji Eun Lee, Hye Ran Yoon, Gu Hwan Kim, Han Wook Yoo, Seong Tae Cho, No Won Chun, Byoung Chunn Jeoung, Hwa Jung Kim, Keong Wook Kim, Seong Nam Kim, Yung A. Kim, Hyun Ah Lee, Jong Young Lee, Yung Chun Lee, Hun Kwan Lim, Keong Sik Oh, Seong Hwan Son, Beong Hee YuKyeong So Wee, Eun Jong Lee, Young Ki Lee, Jung Woo Noh, Seung Jung Kim, Kyu Bok Choi, Suk Hee Yu, Heui Jung Pyo, Young-Joo Kwon

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26 patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α- GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease.

Original languageEnglish
Pages (from-to)415-421
Number of pages7
JournalKorean Journal of Internal Medicine
Volume25
Issue number4
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Fabry Disease
Korea
Chronic Kidney Failure
Dialysis
Maintenance
Serum
Cerebrovascular Disorders
Tandem Mass Spectrometry
Cardiovascular Diseases
Galactosidases
globotriaosylceramide
Left Ventricular Hypertrophy
Rare Diseases
Point Mutation
Reference Values

Keywords

  • End-stage renal disease
  • Fabry disease
  • Globotriaosylceramide

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea. / Kim, Jeong Yup; Hyun, Young Youl; Lee, Ji Eun; Yoon, Hye Ran; Kim, Gu Hwan; Yoo, Han Wook; Cho, Seong Tae; Chun, No Won; Jeoung, Byoung Chunn; Kim, Hwa Jung; Kim, Keong Wook; Kim, Seong Nam; Kim, Yung A.; Lee, Hyun Ah; Lee, Jong Young; Lee, Yung Chun; Lim, Hun Kwan; Oh, Keong Sik; Son, Seong Hwan; Yu, Beong Hee; Wee, Kyeong So; Lee, Eun Jong; Lee, Young Ki; Noh, Jung Woo; Kim, Seung Jung; Choi, Kyu Bok; Yu, Suk Hee; Pyo, Heui Jung; Kwon, Young-Joo.

In: Korean Journal of Internal Medicine, Vol. 25, No. 4, 01.12.2010, p. 415-421.

Research output: Contribution to journalArticle

Kim, JY, Hyun, YY, Lee, JE, Yoon, HR, Kim, GH, Yoo, HW, Cho, ST, Chun, NW, Jeoung, BC, Kim, HJ, Kim, KW, Kim, SN, Kim, YA, Lee, HA, Lee, JY, Lee, YC, Lim, HK, Oh, KS, Son, SH, Yu, BH, Wee, KS, Lee, EJ, Lee, YK, Noh, JW, Kim, SJ, Choi, KB, Yu, SH, Pyo, HJ & Kwon, Y-J 2010, 'Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea', Korean Journal of Internal Medicine, vol. 25, no. 4, pp. 415-421. https://doi.org/10.3904/kjim.2010.25.4.415
Kim, Jeong Yup ; Hyun, Young Youl ; Lee, Ji Eun ; Yoon, Hye Ran ; Kim, Gu Hwan ; Yoo, Han Wook ; Cho, Seong Tae ; Chun, No Won ; Jeoung, Byoung Chunn ; Kim, Hwa Jung ; Kim, Keong Wook ; Kim, Seong Nam ; Kim, Yung A. ; Lee, Hyun Ah ; Lee, Jong Young ; Lee, Yung Chun ; Lim, Hun Kwan ; Oh, Keong Sik ; Son, Seong Hwan ; Yu, Beong Hee ; Wee, Kyeong So ; Lee, Eun Jong ; Lee, Young Ki ; Noh, Jung Woo ; Kim, Seung Jung ; Choi, Kyu Bok ; Yu, Suk Hee ; Pyo, Heui Jung ; Kwon, Young-Joo. / Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea. In: Korean Journal of Internal Medicine. 2010 ; Vol. 25, No. 4. pp. 415-421.
@article{79dd0bf5779a4fa0a0fc13efd9023ee2,
title = "Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea",
abstract = "Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26 patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α- GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease.",
keywords = "End-stage renal disease, Fabry disease, Globotriaosylceramide",
author = "Kim, {Jeong Yup} and Hyun, {Young Youl} and Lee, {Ji Eun} and Yoon, {Hye Ran} and Kim, {Gu Hwan} and Yoo, {Han Wook} and Cho, {Seong Tae} and Chun, {No Won} and Jeoung, {Byoung Chunn} and Kim, {Hwa Jung} and Kim, {Keong Wook} and Kim, {Seong Nam} and Kim, {Yung A.} and Lee, {Hyun Ah} and Lee, {Jong Young} and Lee, {Yung Chun} and Lim, {Hun Kwan} and Oh, {Keong Sik} and Son, {Seong Hwan} and Yu, {Beong Hee} and Wee, {Kyeong So} and Lee, {Eun Jong} and Lee, {Young Ki} and Noh, {Jung Woo} and Kim, {Seung Jung} and Choi, {Kyu Bok} and Yu, {Suk Hee} and Pyo, {Heui Jung} and Young-Joo Kwon",
year = "2010",
month = "12",
day = "1",
doi = "10.3904/kjim.2010.25.4.415",
language = "English",
volume = "25",
pages = "415--421",
journal = "Korean Journal of Internal Medicine",
issn = "0494-4712",
publisher = "Korean Association of Internal Medicine",
number = "4",

}

TY - JOUR

T1 - Serum globotriaosylceramide assay as a screening test for Fabry disease in patients with ESRD on maintenance dialysis in Korea

AU - Kim, Jeong Yup

AU - Hyun, Young Youl

AU - Lee, Ji Eun

AU - Yoon, Hye Ran

AU - Kim, Gu Hwan

AU - Yoo, Han Wook

AU - Cho, Seong Tae

AU - Chun, No Won

AU - Jeoung, Byoung Chunn

AU - Kim, Hwa Jung

AU - Kim, Keong Wook

AU - Kim, Seong Nam

AU - Kim, Yung A.

AU - Lee, Hyun Ah

AU - Lee, Jong Young

AU - Lee, Yung Chun

AU - Lim, Hun Kwan

AU - Oh, Keong Sik

AU - Son, Seong Hwan

AU - Yu, Beong Hee

AU - Wee, Kyeong So

AU - Lee, Eun Jong

AU - Lee, Young Ki

AU - Noh, Jung Woo

AU - Kim, Seung Jung

AU - Choi, Kyu Bok

AU - Yu, Suk Hee

AU - Pyo, Heui Jung

AU - Kwon, Young-Joo

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26 patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α- GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease.

AB - Background/Aims: Fabry disease is an X-linked recessive and progressive disease caused by α-galactosidase A (α-GaL A) deficiency. We sought to assess the prevalence of unrecognized Fabry disease in dialysis-dependent patients and the efficacy of serum globotriaosylceramide (GL3) screening. Methods: A total of 480 patients of 1,230 patients among 17 clinics were enrolled. Serum GL3 levels were measured by tandem mass spectrometry. Additionally, we studied the association between increased GL3 levels and cardiovascular disease, cerebrovascular disease, or left ventricular hypertrophy. Results: Twenty-nine patients had elevated serum GL3 levels. The α-GaL A activity was determined for the 26 patients with high GL3 levels. The mean α-GaL A activity was 64.6 nmol/hr/mg (reference range, 45 to 85), and no patient was identified with decreased α-GaL A activity. Among the group with high GL3 levels, 15 women had a α- GaL A genetics analysis. No point mutations were discovered among the women with high GL3 levels. No correlation was observed between serum GL3 levels and α-GaL A activity; the Pearson correlation coefficient was 0.01352 (p = 0.9478). No significant correlation was observed between increased GL3 levels and the frequency of cardiovascular disease or cerebrovascular disease. Conclusions: Fabry disease is very rare disease in patients with end-stage renal disease. Serum GL3 measurements as a screening method for Fabry disease showed a high false-positive rate. Thus, serum GL3 levels determined by tandem mass spectrometry may not be useful as a screening method for Fabry disease in patients with end stage renal disease.

KW - End-stage renal disease

KW - Fabry disease

KW - Globotriaosylceramide

UR - http://www.scopus.com/inward/record.url?scp=78650971082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650971082&partnerID=8YFLogxK

U2 - 10.3904/kjim.2010.25.4.415

DO - 10.3904/kjim.2010.25.4.415

M3 - Article

C2 - 21179280

AN - SCOPUS:78650971082

VL - 25

SP - 415

EP - 421

JO - Korean Journal of Internal Medicine

JF - Korean Journal of Internal Medicine

SN - 0494-4712

IS - 4

ER -